| Dr Laura Ann Arndorfer, MD | |
|
801 Samish Way, Bellingham, WA 98229-2901 | |
| (360) 255-2505 | |
| (360) 255-2504 |
| Full Name | Dr Laura Ann Arndorfer |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 19 Years |
| Location | 801 Samish Way, Bellingham, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497967848 | NPI | - | NPPES |
| 0296423 | Other | WA | L&I AND CRIME VICTIMS |
| 1497967848 | Medicaid | WA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 42774 (Kentucky) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD60297846 (Washington) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Peacehealth | 9537073960 | 259 |
| Seattle Neuropsychiatric Treatment Center Pllc | 9335215995 | 13 |
News Archive
A unique tail at one end of a protein called Ubc12 stabilizes a molecular workshop that assembles the "on-switch cells" used to accelerate cell replication.
ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
RealTime Laboratories, LLC announced today significant new findings regarding pervasive bacterial presence unique to contaminated drywall. RealTime has identified specific bacteria found only in symptomatic drywall and not in normal domestic drywall that are viable, pervasive and produce hydrogen sulfide and reduced sulfur gases under conditions similar to those found in residences.
› Verified 2 days ago
| Entity Name | Peacehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356309553 PECOS PAC ID: 9537073960 Enrollment ID: O20031118001062 |
News Archive
A unique tail at one end of a protein called Ubc12 stabilizes a molecular workshop that assembles the "on-switch cells" used to accelerate cell replication.
ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
RealTime Laboratories, LLC announced today significant new findings regarding pervasive bacterial presence unique to contaminated drywall. RealTime has identified specific bacteria found only in symptomatic drywall and not in normal domestic drywall that are viable, pervasive and produce hydrogen sulfide and reduced sulfur gases under conditions similar to those found in residences.
› Verified 2 days ago
| Entity Name | Seattle Neuropsychiatric Treatment Center Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609036490 PECOS PAC ID: 9335215995 Enrollment ID: O20080904000528 |
News Archive
A unique tail at one end of a protein called Ubc12 stabilizes a molecular workshop that assembles the "on-switch cells" used to accelerate cell replication.
ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
RealTime Laboratories, LLC announced today significant new findings regarding pervasive bacterial presence unique to contaminated drywall. RealTime has identified specific bacteria found only in symptomatic drywall and not in normal domestic drywall that are viable, pervasive and produce hydrogen sulfide and reduced sulfur gases under conditions similar to those found in residences.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura Ann Arndorfer, MD 801 Samish Way, Bellingham, WA 98229-2901 Ph: (360) 255-2505 | Dr Laura Ann Arndorfer, MD 801 Samish Way, Bellingham, WA 98229-2901 Ph: (360) 255-2505 |
News Archive
A unique tail at one end of a protein called Ubc12 stabilizes a molecular workshop that assembles the "on-switch cells" used to accelerate cell replication.
ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
RealTime Laboratories, LLC announced today significant new findings regarding pervasive bacterial presence unique to contaminated drywall. RealTime has identified specific bacteria found only in symptomatic drywall and not in normal domestic drywall that are viable, pervasive and produce hydrogen sulfide and reduced sulfur gases under conditions similar to those found in residences.
› Verified 2 days ago
Mr. Ronald A Remick, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 609 N Shore Dr, Bellingham, WA 98226 Phone: 360-676-6000 Fax: 360-676-6006 | |
Dr. Neelam Kumari Sampley, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1133 Railroad Ave Ste 100, Bellingham, WA 98225 Phone: 916-835-0144 | |
Zachary Alan Webb, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1345 King St, Bellingham, WA 98229 Phone: 360-676-1696 Fax: 360-676-6636 | |
Ario H Hosseini, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1050 Larrabee Ave Ste 104-510, Bellingham, WA 98225 Phone: 360-200-8962 | |
Dr. Andrew Denzil Pauli, M.D Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 1116 Key St Ste 200, Bellingham, WA 98225 Phone: 360-671-1369 Fax: 360-671-0981 | |
Danielle L Kizer, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2901 Squalicum Pkwy, Attn:behavioral Health Services, Bellingham, WA 98225 Phone: 360-788-6993 Fax: 360-715-6996 | |
Dr. James M Harle, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1112 11th Street, 301, Bellingham, WA 98225 Phone: 360-414-2222 Fax: 360-414-2220 |